Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease

NCT00844285 is registered in ClinicalTrials.gov with UCB BIOSCIENCES, Inc. as lead sponsor.

NCT NCT00844285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00844285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional Long-term Post-Marketing Registry of Patients Treated With Certolizumab Pegol (Cimzia ®) for Crohn's Disease
Lead sponsor
UCB BIOSCIENCES, Inc.
Phase
Observational
Overall status
Completed
Start date
January 30, 2009
Completion date
August 21, 2020
Enrollment
3,072 (actual)
Sites
197

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease